Acute graft-versus-host disease following hematopoietic stem-cell transplantation

Dermatologic Therapy

Volumn 24, Issue 4, 2011, Pages 411-423

  Hu, Stephanie W ^a   Cotliar, Jonathan ^b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

bone marrow transplantation; graft versus host disease; stem cell transplantation

Indexed keywords

ANTHRACYCLINE; ANTIVIRUS AGENT; BILIRUBIN; CALCINEURIN INHIBITOR; CD34 ANTIGEN; COMPLEMENT COMPONENT C3; CORTICOSTEROID; CYCLOSPORIN; CYTARABINE; DACLIZUMAB; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 8; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PALIFERMIN; PLACEBO; PLERIXAFOR; SCATTER FACTOR; STEROID; TACROLIMUS; TAXANE DERIVATIVE; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ANXIETY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BILIRUBIN BLOOD LEVEL; CHRONIC GRAFT VERSUS HOST DISEASE; CORTICOSTEROID THERAPY; DEPRESSION; DESQUAMATION; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DONOR; ERYTHEMA; GRAFT FAILURE; GRAFT INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HLA MATCHING; HUMAN; HYPOTHYROIDISM; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOFLUORESCENCE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; LIVER VENOOCCLUSIVE DISEASE; LUNG INJURY; MEASLES LIKE RASH; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; PERIPHERAL BLOOD STEM CELL; RASH; SEXUAL DYSFUNCTION; SKIN BIOPSY; SKIN MANIFESTATION; SKIN TOXICITY; STEM CELL EXPANSION; STEM CELL MOBILIZATION; STOMATITIS; SURGICAL INJURY; TREATMENT INDICATION;

ACUTE DISEASE; BONE MARROW TRANSPLANTATION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; NEOPLASMS;

EID: 80052763400     PISSN: 13960296     EISSN: 15298019     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2011.01436.x     Document Type: Article

References (123)

1. Welniak LA, Blazar BR, Murphy WJ,. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol 2007: 25: 139-170. (Pubitemid 46697905)
2. Lake RA, Robinson BW,. Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 2005: 5: 397-405.
3. Anderlini P, Rizzo JD, Nugent ML, Schmitz N, Champlin RE, Horowitz MM,. Peripheralblood stem cell donation: an analysis from the International Bone Marrow Transplant Registry (IBMTR) and European Group for Blood and Marrow Transplant (BMT) databases. Bone Marrow Transplant 2001: 27: 689-692. (Pubitemid 32409442)
4. Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin JH,. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation: a meta-analysis. J Clin Oncol 2001: 19: 3685-3691. (Pubitemid 32786281)
5. Stewart BL, Storer B, Storek J, et al,. Duration of immunosuppressive treatment for chronic graft-versus-host disease. Blood 2004: 104: 3501-3506. (Pubitemid 39564419)
6. Levesque J-P, Liu F, Simmons PJ, et al,. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004: 104: 65-72. (Pubitemid 38879839)
7. Flomenberg N, Devine SM, DiPersio JF, et al,. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005: 106: 1867-1874. (Pubitemid 41208607)
8. Kline J, Subbiah S, Lazarus HM, van Besien K,. Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance. Bone marrow transplantation 2008: 41 (6): 505-513. (Pubitemid 351472141)
9. Brenner MK, Rill DR, Moen RC, et al,. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993: 341: 85-86. (Pubitemid 23028118)
10. Stewart AK, Vescio R, Schiller G, et al,. Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J Clin Oncol 2001: 19: 3771-3779. (Pubitemid 32844791)
11. Wagner JE, Barker JN, DeFor TE, et al,. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002: 100: 1611-1618. (Pubitemid 34925136)
12. Barker JN, Weisdorf DJ, DeFor TE, et al,. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005: 105: 1343-1347. (Pubitemid 40170912)
13. Aversa F, Tabilio A, Velardi A, et al,. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998: 339: 1186-1193. (Pubitemid 28482127)
14. Ruggeri L, Capanni M, Urbani E, et al,. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002: 295: 2097-2100. (Pubitemid 34229476)
15. Copelan EA,. Hematopoietic stem-cell transplantation. N Engl J Med 2006: 354: 1813-1826.
16. DeLeve LD, Shulman HM, McDonald GB,. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002: 22: 27-42.
17. Kallianpur AR, Hall LD, Yadav M, et al,. The hemochromatosis C282Y allele: a risk factor for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2005: 35: 1155-1164. (Pubitemid 40895171)
18. Srivastava A, Poonkuzhali B, Shaji RV, et al,. Glutathione S-transferase M1 polymorphism: a risk factor for hepatic venoocclusive disease in bone marrow transplantation. Blood 2004: 104: 1574-1577. (Pubitemid 39166540)
19. Bornhauser M, Storer B, Slattery JT, et al,. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003: 102: 820-826. (Pubitemid 36917770)
20. Hogan WJ, Maris M, Storer B,. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004: 103: 78-84. (Pubitemid 38029921)
21. Cooke KR, Yanik G,. Acute lung injury after allogeneic stem cell transplantation: is the lung a target of acute graft-versus-host disease? Bone Marrow Transplant 2004: 34: 753-765. (Pubitemid 39467887)
22. Yanik G, Hellerstedt B, Custer J, et al,. Etanercept (Enbrel) administration for idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002: 8: 395-400.
23. Meyers JD, Flournoy N, Thomas ED,. Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years' experience. Rev Infect Dis 1982: 4: 1119-1132.
24. Tivol E, Komorowski R, Drobyski WR,. Emergent autoimmunity in graft-versus-host disease. Blood 2005: 105: 4885-4891. (Pubitemid 40807318)
25. Dann EJ, Epelbaum R, Avivi I, et al,. Fertility and ovarian function are preserved in women treated with an intensified regimen of cyclophosphamide, adriamycin, vincristine and prednisone (Mega-CHOP) for non-Hodgkin lymphoma. Hum Reprod 2005: 20: 2247-2249. (Pubitemid 41418514)
26. Lass A, Akagbosu F, Brinsden P,. Sperm banking and assisted reproduction treatment for couples following cancer treatment of the male partner. Hum Reprod Update 2001: 7: 370-377. (Pubitemid 32655322)
27. Sanders JE, Guthrie KA, Hoffmeister PA, Woolfrey AE, Carpenter PA, Appelbaum FR,. Final adult height of patients who received hematopoietic cell transplantation in childhood. Blood 2005: 105: 1348-1354. (Pubitemid 40170913)
28. Curtis RE, Rowlings PA, Deeg HJ, et al,. Solid cancers after bone marrow transplantation. N Engl J Med 1997: 336: 897-904. (Pubitemid 27137189)
29. Krishnan A, Bhatia S, Slovak ML, et al,. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors. Blood 2000: 95: 1588-1593. (Pubitemid 30120817)
30. Syrjala KL, Langer SL, Abrams JR, Storer BE, Martin PJ,. Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls. J Clin Oncol 2005: 23: 6596-6606. (Pubitemid 46190253)
31. Spielberger R, Stiff P, Bensinger W, et al,. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004: 351: 2590-2598. (Pubitemid 39628580)
32. Billingham RE,. The biology of graft-versus-host reactions. Harvey Lect 1966: 62: 21-78.
33. Korngold R, Sprent J, eds. Purified T cell subsets and lethal graft-versus-host disease in mice. In:, Gale CR, ed. Progress in bone marrow transplant. New York, NY: Alan R. Liss, Inc., 1987: 213-218.
34. Kernan NA, Collins NH, Juliano LL, et al,. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986: 68: 770-773. (Pubitemid 16008184)
35. Petersdorf EW, Longton GM, Anasetti C, et al,. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, B, DR identical unrelated donor marrow transplantation. Blood 1995: 86: 1606-1613.
36. Krensky AM, Weiss A, Crabtree G, Davis MM, Parham P,. T-lymphocyte-antigen interactions in transplant rejection. N Engl J Med 1990: 322: 510-517. (Pubitemid 20067828)
37. Loiseau P, Busson M, Balere ML, et al,. HLA association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. Biol Blood Marrow Transplant 2007: 13: 965-974. (Pubitemid 47055388)
38. Center for International Blood and Marrow Transplant Research. Report, C.f.I.B.a.M.T.R.C.P., January-December 2008.
39. Goulmy E, Schipper R, Pool J, et al,. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996: 334: 281-285. (Pubitemid 26033083)
40. Bleakley M, Riddell SR,. Molecules and mechanisms of the graft-versus-leukemia effect. Nat Rev Cancer 2004: 4: 371-380.
41. Weisdorf D, Hakke R, Blazar B, et al,. Risk factors for acute graft-versus-host disease in histocompatible donor bone marrow transplantation. Transplantation 1991: 51: 1197-1203.
42. Eisner MD, August CS,. Impact of donor and recipient characteristics on the development of acute and chronic graft-versus-host disease following pediatric bone marrow transplantation. Bone Marrow Transplant 1995: 15: 663-668.
43. Martin P, August CS, Souillet G,. Clinical and pharmacological risk factors for acute graft-versus-host disease after paediatric bone marrow transplantation from matched-sibling or unrelated donors. Bone Marrow Transplant 2003: 32: 881-887. (Pubitemid 37369265)
44. Gale RP, Bortin MM, van Bekkum DW, et al,. Risk factors for acute graft-versus-host disease. Br J Haematol 1987: 67: 397-406. (Pubitemid 18032036)
45. Nash RA, Pepe MS, Storb R, et al,. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992: 80: 1838-1845.
46. Hahn T, McCarthy PL Jr, Zhang MJ, et al,. Risk factors for acute graft-versus-host disease after human leukocyte antigen-identical sibling transplants for adults with leukemia. J Clin Oncol 2008: 26: 5728-5734.
47. Vigorito AC, Azevedo WM, Marques JF, et al,. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant 1998: 22: 1145-1151. (Pubitemid 29021122)
48. Eapen M, Rubinstein P, Zhang MJ, et al,. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet 2007: 369: 1947-1954. (Pubitemid 46874578)
49. Antin JH, Ferrara JL,. Cytokine dysregulation and acute graft-versus-host disease. Blood 1992: 80: 2964-2968. (Pubitemid 23004498)
50. Cavet J, Middleton PG, Segall M, Noreen H, Davies SM, Dickinson AM,. Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. Blood 1999: 94: 3941-3946.
51. Lin MT, Storer B, Martin PJ, et al,. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. N Engl J Med 2003: 349: 2201-2210. (Pubitemid 37485136)
52. Dickinson AM, Charron D,. Non-HLA immunogenetics in hematopoietic stem cell transplantation. Curr Opin Immunol 2005: 17: 517-525. (Pubitemid 41207956)
53. Ferrara JL, Deeg HJ,. Graft-versus-host disease. N Engl J Med 1991: 324: 667-674.
54. Hess AD,. Reconstitution of self-tolerance after hematopoietic stem cell transplantation. Immunol Res 2010: 47: 143-152.
55. Glucksberg H, Storb R, Fefer A, et al,. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974: 18: 295-304.
56. Filipovich AH, Weisdorf D, Pavletic S, et al,. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 2005: 11: 945-956. (Pubitemid 41754712)
57. Rowlings PA, Przepiorka D, Klein JP, et al,. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997: 97: 855-864. (Pubitemid 27321388)
58. Antin JH, Bierer BE, Smith BR, et al,. Selectivedepletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991: 78: 2139-2149.
59. Spitzer TR,. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001: 27: 893-898. (Pubitemid 32529870)
60. Johnson ML, Farmer ER,. Graft-versus-host reactions in dermatology. J Am Acad Dermatol 1998: 38: 369-392. (Pubitemid 28125520)
61. Crider MK, Jansen J, Norins AL, McHale MS,. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986: 122: 1023-1027. (Pubitemid 16053116)
62. Bolognia JL, Cooper DL, Glusac EJ,. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008: 59 (3): 524-529.
63. Horn TD, Redd JV, Karp JE, Beschorner WE, Burke PJ, Hood AF,. Cutaneous eruptions of lymphocyte recovery. Arch Dermatol 1989: 125 (11): 1512-1517. (Pubitemid 19280882)
64. Washington K, Jagasia M,. Pathology of graft-versus-host disease in the gastrointestinal tract. Hum Pathol 2009: 40 (7): 909-917.
65. Quaglia A, Duarte R, Patch D, Ngianga-Bakwin K, Dhillon AP,. Histopathology of graft versus host disease of the liver. Histopathology 2007: 50 (6): 727-738. (Pubitemid 46683932)
66. Sale G, Lerner K, Barker E, Shulman H, Thomas E,. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 1977: 89: 621-636.
67. Kohler S, Hendrickson MR, Chao NJ, Smoller BR,. Value of skin biopsies in assessing prognosis and progression of acute graft-versus-host disease. Am J Surg Pathol 1997: 21 (9): 988-996. (Pubitemid 27407282)
68. Zhou Y, Barnett MJ, Rivers JK,. Clinical significance of skin biopsies in the diagnosis and management of graft-vs-host disease in early postallogeneic bone marrow transplantation. Arch Dermatol 2000: 136: 717-721. (Pubitemid 30407426)
69. Kuykendall TD, Smoller BR,. Lack of specificity in skin biopsy specimens to assess for acute graft-versus-host disease in initial 3 weeks after bone-marrow transplantation. J Am Acad Dermatol 2003: 49 (6): 1081-1085. (Pubitemid 37475481)
70. Lerner KG, Kao GF, Strob R, Buckner CD, Clift RA, Thomas ED,. Histopathology of graft-versus-host reaction (GVHR) in human recipients of marrow from HLA-matched sibling donors. Transplant Proc 1974: 6: 367-371.
71. Tsoi M, Storb R, Jones E, et al,. Deposition of IgM and complement at the dermoepidermal junction in acute and chronic cutaneous graft-vs-host disease in man. J Immunol 1978: 120: 1485-1492. (Pubitemid 8400378)
72. Gilliam A, Whitaker-Menezes D, Korngold R, Murphy G,. Apoptosis is the predominant form of epithelial target cell injury in acute experimental graft versus host disease. J Invest Dermatol 1996: 107: 377-383. (Pubitemid 26284347)
73. Elliott C, Sloane J, Pallett C, Sanderson K,. Cutaneous leukocyte composition after human allogeneic bone marrow transplantation: relationship to marrow purging, histology, and clinical rash. Histopathology 1988: 12: 1-16.
74. Acevedo A, Aramburu J, Lopez J, Fernandez-Herrera J, Fernandez-Ranada J, Lopez-Botet M,. Identification of natural killer (NK) cells in lesions of human cutaneous graft-versus-host disease: expression of a novel NK-associated surface antigen (Kp43) in mononuclear infiltrates. J Invest Dermatol 1991: 97: 659-666.
75. Paller S, Nelson A, Steffen L, Gottschalk L, Kaiser H,. T-lymphocyte subsets in the lesional skin of allogeneic and autologous bone marrow transplant patients. Arch Dermatol 1988: 124: 1795-1801. (Pubitemid 19010097)
76. Volc-Platzer B, Rappersberger K, Mosberger I, et al,. Sequential immunohistologic analysis of the skin following allogeneic bone marrow transplantation. J Invest Dermatol 1988: 91: 162-168.
77. Sviland L, Pearson A, Green MA, et al,. Immunopathology of early graft-versus-host disease-a prospective study of skin, rectum, and peripheral blood in allogeneic and autologous bone marrow transplant recipients. Transplantation 1991: 52: 1029-1036.
78. Sloane J, Thomas J, Imrie S, Easton D, Powles R,. Morphological and immunohistological changes in the skin in allogeneic bone marrow recipients. J Clin Pathol 1984: 37: 919-930. (Pubitemid 14065067)
79. Kay V, Neumann P, Kersey J,. Identity of immune cells in graft-versus-host disease in the skin: analysis using monoclonal antibodies by indirect immunofluorescence. Am J Pathol 1984: 116: 436-440. (Pubitemid 14034010)
80. Lever R, Turbitt M, Mackie R,. A prospective study of the histological changes in the skin in patients receiving bone marrow transplants. Br J Dermatol 1986: 114: 161-170. (Pubitemid 16131422)
81. Dreno B, Milpied N, Harousseau J, et al,. Cutaneous immunological studies in diagnosis of acute graft-versus-host disease. Br J Dermatol 1986: 114: 7-15. (Pubitemid 16128757)
82. Atkinson K, Munro V, Vasak E, Biggs J,. Mononuclear cell subpopulations in the skin defined by monoclonal antibodies after HLA-identical sibling marrow transplantation. Br J Dermatol 1986: 114: 145-160. (Pubitemid 16131421)
83. Girolomoni G, Pincelli C, Zambruno G, et al,. Immunohistochemistry of cutaneous graft-versus-host disease after allogeneic bone marrow transplantation. J Dermatol 1991: 18: 314-323.
84. Leskinen R, Taskinen E, Volin L, Ruutu T, Hayry P,. Immunohistology of skin and rectum biopsies in bone marrow transplant recipients. APMIS 1992: 100: 1115-1122. (Pubitemid 23038712)
85. Lunn RA, Sumar N, Bansal AS, Treleaven J,. Cytokine profiles in stem cell transplantation: possible use as apredictor of graft-versus-host disease. Hematology 2005: 10: 107-114. (Pubitemid 41800784)
86. Srinivasan R, Daniels J, Fusaro V, et al,. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006: 34: 796-801. (Pubitemid 43737094)
87. Wissinger EM, Schiffer E, Hertenstein B, et al,. Proteomic patterns predict acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 2007: 109: 5511-5519. (Pubitemid 46890577)
88. Hori T, Naishiro Y, Sohma H, et al,. CCL8 is a potential molecular candidate for the diagnosis of graft-versus-host disease. Blood 2008: 118: 4403-4412.
89. Paczesny S, Krijanovski OI, Braun TM, et al,. A biomarker panel for acute graft-versus-host disease. Blood 2009: 113: 273-278.
90. Paczesny S, Braun TM, Levine JE, et al,. Elafin is a biomarker of graft-versus-host disease of the skin. Sci Transl Med 2010: 2: 1-19.
91. Storb R, Deeg HJ, Whitehead J, et al,. Methotrexate and cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986: 314: 729-735. (Pubitemid 16124386)
92. Ratanatharathorn V, Nash RA, Przepiorka D, et al,. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998: 92: 2303-2314. (Pubitemid 28452971)
93. Hiraoka A, Ohashi Y, Okamoto S, et al,. Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001: 28: 181-185. (Pubitemid 32725719)
94. Horowitz MM, Przepiorka D, Bartels P, et al,. Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. Biol Blood Marrow Transplant 1999: 5: 180-186.
95. Ram R, Gafter-Gvili A, Yeshurun M, Paul M, Raanani P, Shpilberg O,. Prophylaxis regimens for GVHD: systematic review and meta-analysis. Bone Marrow Transplant 2009: 43: 643-653.
96. Nash RA, Antin JH, Karanes C, et al,. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000: 96: 2062-2068.
97. Bolwell B, Sobecks R, Pohlman B, et al,. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004: 34: 621-625. (Pubitemid 39341543)
98. Bornhauser M, Schuler U, Porksen G, et al,. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 1999: 67: 499-504. (Pubitemid 29114207)
99. Mohty M, de Lavallade H, Faucher C, et al,. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 2004: 34: 527-530. (Pubitemid 39264044)
100. Kasper C, Sayer HG, Mugge LO, et al,. Combined standard graft-versus-host disease (GvHD) prophylaxis with mycophenolate mofetil (MMF) in allogeneic peripheral blood stem cell transplantation from unrelated donors. Bone Marrow Transplant 2004: 33: 65-69. (Pubitemid 38159706)
101. Vogelsang GB, Arai S,. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplant 2001: 27: 1255-1262. (Pubitemid 32655393)
102. Niederwieser D, Maris M, Shizuru JA, et al,. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003: 101: 1620-1629. (Pubitemid 36182543)
103. Marmont AM, Horowitz MM, Gale RP, et al,. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991: 78: 2120-2130.
104. Martin PJ, Hansen JA, Torok-Storb B,. Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988: 3: 445-456.
105. O'Reilly OJ,. T-cell depletion and allogeneic bone marrow transplantation. Semin Hematol 1992: 29: 20-26.
106. Kottaridis PD, Milligan DW, Chopra R, et al,. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation. Cytotherapy 2001: 3: 197-201. (Pubitemid 33039657)
107. Bacigalupo A, Lamparelli T, Bruzzi P,. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 2001: 98: 2942-2947.
108. Reddy P, Ferrara JL,. Immunobiology of acute graft-versus-host disease. Blood 2003: 17: 187-194. (Pubitemid 37356389)
109. Hill GR, Ferrara JL,. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000: 95: 2754-2759. (Pubitemid 30235880)
110. Xun CQ, Thompson JS, Jennings CD, Brown SA, Widmer MB,. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 1994: 83: 2360-2367.
111. Couriel DR, Saliba RM, Giralt S, et al,. Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004: 10: 178-185. (Pubitemid 38262880)
112. Choi SW, Kitko CL, Braun T, et al,. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008: 112: 1539-1542.
113. Matzinger P,. The danger model: a renewed sense of self. Science 2002: 296: 301-305. (Pubitemid 34303674)
114. Shlomchik WD, Couzens MS, Tang CB, et al,. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999: 285: 412-415. (Pubitemid 29343964)
115. Chao NJ, Holler E, Deeg HJ, eds. Prophylaxis and treatment of acute graft-versus-host disease. In:, Ferrara JLM CK, Deeg HJ, eds. Graft-versus-host disease, 3rd ed. New York, NY: Dekker, 2005: 459-479.
116. Penas PF, Fernandez-Herrera J, Garcia-Diez A,. Dermatologic treatment of cutaneous graft versus host disease. Am J Clin Dermatol 2004: 5: 403-416. (Pubitemid 40175258)
117. Couriel D, Caldera H, Champlin R, Komanduri K,. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004: 101: 1936-1946. (Pubitemid 39425368)
118. Higman MA, Vogelsang GB,. Chronic graft versus host disease. Br J Haematol 2004: 125: 435-454. (Pubitemid 38916189)
119. Ruutu T, Niederwieser D, Gratwohl A, Apperley JF,. A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT), chronic leukemia working party of the EBMT. Bone Marrow Transplant 1997: 19: 759-764. (Pubitemid 27207889)
120. Saliba RM, de Lima M, Giralt S, et al,. Hyperacute GVHD: risk factors, outcomes, and clinical implications. Blood 2007: 109: 2751-2758. (Pubitemid 46482067)
121. Hings IM, Filipovich AH, Miller WJ, et al,. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment: a prospective randomized trial. Transplantation 1993: 56: 577-580. (Pubitemid 23293018)
122. Bacigalupo A, van Lint MT, Frassoni F, et al,. High dose bolus methylprednisolone for the treatment of acute graft versus host disease. Blut 1983: 46: 125-132. (Pubitemid 13160123)
123. Kanojia MD, Anagnostou AA, Zander AR, et al,. High-dose methylprednisolone treatment for acute graft-versus-host disease after bone marrow transplantation in adults. Transplantation 1984: 37: 246-249. (Pubitemid 14164935)